1. Home
  2. RIGL vs VTLE Comparison

RIGL vs VTLE Comparison

Compare RIGL & VTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • VTLE
  • Stock Information
  • Founded
  • RIGL 1996
  • VTLE 2006
  • Country
  • RIGL United States
  • VTLE United States
  • Employees
  • RIGL N/A
  • VTLE N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • VTLE
  • Sector
  • RIGL Health Care
  • VTLE
  • Exchange
  • RIGL Nasdaq
  • VTLE Nasdaq
  • Market Cap
  • RIGL 537.6M
  • VTLE 631.5M
  • IPO Year
  • RIGL 2000
  • VTLE 2011
  • Fundamental
  • Price
  • RIGL $29.48
  • VTLE $15.85
  • Analyst Decision
  • RIGL Buy
  • VTLE Hold
  • Analyst Count
  • RIGL 5
  • VTLE 11
  • Target Price
  • RIGL $38.20
  • VTLE $26.11
  • AVG Volume (30 Days)
  • RIGL 492.6K
  • VTLE 638.3K
  • Earning Date
  • RIGL 11-04-2025
  • VTLE 10-31-2025
  • Dividend Yield
  • RIGL N/A
  • VTLE N/A
  • EPS Growth
  • RIGL N/A
  • VTLE N/A
  • EPS
  • RIGL 5.43
  • VTLE N/A
  • Revenue
  • RIGL $267,921,000.00
  • VTLE $1,935,411,000.00
  • Revenue This Year
  • RIGL $59.93
  • VTLE $0.55
  • Revenue Next Year
  • RIGL N/A
  • VTLE N/A
  • P/E Ratio
  • RIGL $5.44
  • VTLE N/A
  • Revenue Growth
  • RIGL 105.62
  • VTLE 5.26
  • 52 Week Low
  • RIGL $13.57
  • VTLE $12.30
  • 52 Week High
  • RIGL $43.72
  • VTLE $36.72
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 46.18
  • VTLE 47.44
  • Support Level
  • RIGL $29.30
  • VTLE $15.65
  • Resistance Level
  • RIGL $30.94
  • VTLE $16.35
  • Average True Range (ATR)
  • RIGL 1.26
  • VTLE 0.71
  • MACD
  • RIGL 0.38
  • VTLE -0.03
  • Stochastic Oscillator
  • RIGL 53.61
  • VTLE 34.86

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About VTLE Vital Energy Inc. par value $0.01 per share

Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.

Share on Social Networks: